Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BoNT/A-DP versus Botox Cosmetic for glabellar frown lines
2019-003481-41Phase 2Completed
- Sponsor
- Croma-Pharma
- Start
- Oct 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of botulinum neurotoxin type A-DP and botulinum toxin type A in glabellar furrowing (2 arms), sponsored by Croma-Pharma. Primary endpoint: Week 4 responder rate by investigator assessment. Started Oct 2019; status: completed.
02
Drugs
botulinum neurotoxin type A-DPbotulinum toxin type A
03
Conditions
glabellar furrowing
Beyond the preview
Go deeper on 2019-003481-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003481-41.